摘要
目的：为了评价帕米膦酸二钠对骨转移所致高血钙和骨痛的治疗作用。方法：本临床研究为随机化对照研究，共收治有溶骨性骨转移病灶的病人５８例。病人被随机分为两组，治疗组３０例，采用帕米膦酸二钠３０ｍｇ／天，共用１天；对照组２８例，采用骨磷３００ｍｇ／天，共用５天。帕米膦酸二钠和骨膦均加入５％的葡萄糖溶液５００ｍｌ中静脉滴注４个小时。血钙下降率和骨痛的缓解率作为评价指标。结果：治疗组血钙升高者９例，治疗后第７天８例血钙均降至正常范围，下降率为８９％；对照组血钙升高者３例，经治疗后有２例降至正常范围，下降率为６６．６６％。疼痛的缓解方面，治疗组和对照组用药前均有骨痛，治疗后，治疗组和对照组分别为１９例和１１例疼痛缓解，疼痛缓解率分别为６３．３３％和３９．２％。治疗组血钙下降率和疼痛缓解率均高于对照组（８９％比６６．６６％和６３．３３％比３９．２９％），但两组之间无显著性差异（Ｐ＞０．０５）。毒副作用方面，两组病人在用药过程中均未见有严重不良反应，病人耐受良好。结论：帕米膦酸二钠是一种治疗恶性肿瘤骨转移引起的高血钙和骨痛的有效药物，临床使用方便，病人耐受性良好。
Purpose: The purpose of this clinical trial is to evalute the effect of Pamidronate in the treatment of bone metastatic diseases. Method: In this randomized comparative study, 58 patients with bone lytic metastasis were treated. Pateints were randomly divided into two grops, 30 cases in the treatment group and 28 in the control group. Patients in the treatment group were treated with Pamidronate 30 mg/Day for one day. In the control group, patients were treated with Clodronate 300 mg/Day for 5 days. Pamidronate and Clodronate were dissolved in 5% G.S. 500 ml and given by infusion for 4 hours. Serum calcium lercl and pain release were used as crateria of response. Result: 89% hypercalcaemia cases (8/9) were controled in the treatment group after 7 days compared with 66.66% (2/3) in control group. The rate of pain release in the two groups were 63.33% and 39.29% respectiely. Treatment group appears to be superior to control group in the control of serum calcium and apin release, but there are no statistically differences between the two groups. Patients were well tolerated. Conclusion: theis trial confirmed that Pamidronate (APD) was an effective drug in the treatment of cancer-associated hypercalcaemia and cancer-pain related with bone metastasis. The drug is conveniently used and well tolerated.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1997年第6期430-432,共3页
Chinese Journal of Cancer
